153 related articles for article (PubMed ID: 34333670)
1. Effects of medical service fee revision on reducing irrational psychotropic polypharmacy in Japan: an interrupted time-series analysis.
Okada Y; Akazawa M
Soc Psychiatry Psychiatr Epidemiol; 2022 Feb; 57(2):411-422. PubMed ID: 34333670
[TBL] [Abstract][Full Text] [Related]
2. Changes in Prescription of Psychotropic Drugs After Introduction of Polypharmacy Reduction Policy in Japan Based on a Large-Scale Claims Database.
Hirano Y; Ii Y
Clin Drug Investig; 2019 Nov; 39(11):1077-1092. PubMed ID: 31399894
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of medical fee revisions for psychotropic polypharmacy in patients with mood disorders in Japan: An interrupted time-series analysis using a nationwide inpatient database.
Yamazaki R; Ohbe H; Matsuda Y; Kito S; Shigeta M; Morita K; Matsui H; Fushimi K; Yasunaga H
Asian J Psychiatr; 2023 Jun; 84():103581. PubMed ID: 37086613
[TBL] [Abstract][Full Text] [Related]
4. Prescribing Trends Psychotropic Drugs Against Children and Adolescents and Association with Polypharmacy Reduction Policy for Psychotropic Drugs: Based on Japanese National Database Survey.
Park J; Okui T; Nakashima N
Stud Health Technol Inform; 2022 Jun; 290():1132-1133. PubMed ID: 35673241
[TBL] [Abstract][Full Text] [Related]
5. Risk of Extrapyramidal Syndromes Associated With Psychotropic Polypharmacy: A Study Based on Large-Scale Japanese Claims Data.
Hirano Y
Ther Innov Regul Sci; 2020 Mar; 54(2):259-268. PubMed ID: 31933179
[TBL] [Abstract][Full Text] [Related]
6. How psychotropic polypharmacy in schizophrenia begins: a longitudinal perspective.
Shinfuku M; Uchida H; Tsutsumi C; Suzuki T; Watanabe K; Kimura Y; Tsutsumi Y; Ishii K; Imasaka Y; Mimura M; Kapur S
Pharmacopsychiatry; 2012 Jun; 45(4):133-7. PubMed ID: 22174025
[TBL] [Abstract][Full Text] [Related]
7. National trends in psychotropic medication polypharmacy in office-based psychiatry.
Mojtabai R; Olfson M
Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour.
Deb S; Unwin G; Deb T
J Intellect Disabil Res; 2015 Jan; 59(1):11-25. PubMed ID: 24450426
[TBL] [Abstract][Full Text] [Related]
9. Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics.
Yang SY; Chen LY; Najoan E; Kallivayalil RA; Viboonma K; Jamaluddin R; Javed A; Hoa DTQ; Iida H; Sim K; Swe T; He YL; Park Y; Ahmed HU; De Alwis A; Chiu HF; Sartorius N; Tan CH; Chong MY; Shinfuku N; Lin SK
Psychiatry Clin Neurosci; 2018 Aug; 72(8):572-579. PubMed ID: 29761577
[TBL] [Abstract][Full Text] [Related]
10. Trends in psychotropic drug prescribing in Norwegian nursing homes from 1997 to 2009: a comparison of six cohorts.
Ruths S; Sørensen PH; Kirkevold Ø; Husebø BS; Krüger K; Halvorsen KH; Selbaek G
Int J Geriatr Psychiatry; 2013 Aug; 28(8):868-76. PubMed ID: 23147389
[TBL] [Abstract][Full Text] [Related]
11. Estimated model of psychotropic polypharmacy for bipolar disorder: Analysis using patients' and practitioners' parameters in the MUSUBI study.
Adachi N; Azekawa T; Edagawa K; Goto E; Hongo S; Kato M; Katsumoto E; Kikuchi T; Kubota Y; Miki K; Nakagawa A; Tsuboi T; Ueda H; Watanabe K; Watanabe Y; Yasui-Furukori N; Yoshimura R
Hum Psychopharmacol; 2021 Mar; 36(2):e2764. PubMed ID: 33089907
[TBL] [Abstract][Full Text] [Related]
12. Association of the Centers for Medicare & Medicaid Services' National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014.
Maust DT; Kim HM; Chiang C; Kales HC
JAMA Intern Med; 2018 May; 178(5):640-647. PubMed ID: 29550856
[TBL] [Abstract][Full Text] [Related]
13. Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders.
Rhee TG; Rosenheck RA
J Affect Disord; 2019 Jun; 252():450-457. PubMed ID: 31004825
[TBL] [Abstract][Full Text] [Related]
14. Non-adherence with psychotropic medications in the general population.
Bulloch AG; Patten SB
Soc Psychiatry Psychiatr Epidemiol; 2010 Jan; 45(1):47-56. PubMed ID: 19347238
[TBL] [Abstract][Full Text] [Related]
15. A cross sectional study of psychotropic medicine use in Australia in 2018: A focus on polypharmacy.
Brett J; Pearson SA; Daniels B; Wylie CE; Buckley NA
Br J Clin Pharmacol; 2021 Mar; 87(3):1369-1377. PubMed ID: 32881057
[TBL] [Abstract][Full Text] [Related]
16. [Profile of prescription of psychotropic drugs in a National Fund of Social Foresight Organisation in Morocco].
Belkacem A
Encephale; 2006; 32(3 Pt 1):335-40. PubMed ID: 16840927
[TBL] [Abstract][Full Text] [Related]
17. Trends in antipsychotic prescriptions for Japanese outpatients during 2006-2012: a descriptive epidemiological study.
Kochi K; Sato I; Nishiyama C; Tanaka-Mizuno S; Doi Y; Arai M; Fujii Y; Matsunaga T; Ogawa Y; Furukawa TA; Kawakami K
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):642-656. PubMed ID: 28266090
[TBL] [Abstract][Full Text] [Related]
18. Psychotropic medication in a randomly selected group of citizens receiving residential or home care.
Futtrup TB; Helnæs AK; Schultz H; Jensen M; Reuther LØ
Dan Med J; 2014 Dec; 61(12):A4965. PubMed ID: 25441727
[TBL] [Abstract][Full Text] [Related]
19. Prescribing Practices for Patients With Borderline Personality Disorder During Psychiatric Hospitalizations.
Romanowicz M; Schak KM; Vande Voort JL; Leung JG; Larrabee BR; Palmer BA
J Pers Disord; 2020 Dec; 34(6):736-749. PubMed ID: 30742548
[TBL] [Abstract][Full Text] [Related]
20. A ten-year review of the effect of OBRA-87 on psychotropic prescribing practices in an academic nursing home.
Lantz MS; Giambanco V; Buchalter EN
Psychiatr Serv; 1996 Sep; 47(9):951-5. PubMed ID: 8875659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
